The Presence of a CMV Immunodominant Allele in the Recipient Is Associated With Increased Survival in CMV Positive Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation.

CMV DNA terminase complex inhibitor graft versus host disease haploidentical immunodominant allele transplant outcomes

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2019
Historique:
received: 24 07 2019
accepted: 27 08 2019
entrez: 15 10 2019
pubmed: 15 10 2019
medline: 15 10 2019
Statut: epublish

Résumé

Specific major histocompatibility (MHC) class I alleles dominate anti-CMV responses in a hierarchal manner. These CMV immunodominant (IMD) alleles are associated with a higher magnitude and frequency of cytotoxic lymphocyte responses as compared to other human leukocyte antigen (HLA) alleles. CMV reactivation has been associated with an increased incidence of graft-vs.-host disease and non-relapse mortality, as well as protection from relapse in HLA-matched HSCT settings. Less is known about the impact of CMV reactivation on these major outcomes after haploidentical (HI) HSCT, an increasingly applied therapeutic option. In HI HSCT, the efficiency of the immune response is decreased due to the immune suppression required to cross the MHC barrier as well as MHC mismatch between presenting and responding cells. We hypothesized that the presence of a CMV IMD allele would increase the efficiency of CMV responses after HI HSCT potentially impacting CMV-related outcomes. In this retrospective, multivariable review of 216 HI HSCT patients, we found that CMV+ recipients possessing at least 1 of 5 identified CMV IMD alleles had a lower hazard of death (HR = 0.40,

Identifiants

pubmed: 31608225
doi: 10.3389/fonc.2019.00888
pmc: PMC6758597
doi:

Types de publication

Journal Article

Langues

eng

Pagination

888

Informations de copyright

Copyright © 2019 Grosso, Leiby, Carabasi, Filicko-O'Hara, Gaballa, O'Hara, Wagner and Flomenberg.

Références

J Immunol. 2007 Apr 1;178(7):4455-65
pubmed: 17372003
J Infect. 2016 Sep;73(3):261-70
pubmed: 27311748
Blood. 2010 Oct 7;116(14):2411-9
pubmed: 20581313
Blood. 2004 Jan 15;103(2):630-8
pubmed: 12947002
Blood. 2013 Aug 15;122(7):1316-24
pubmed: 23744585
Nat Commun. 2016 Oct 27;7:13264
pubmed: 27786275
Bone Marrow Transplant. 2019 Jul;54(7):1004-1012
pubmed: 30401965
Bone Marrow Transplant. 2017 Oct;52(10):1465-1467
pubmed: 28759027
Transpl Infect Dis. 2019 Aug;21(4):e13096
pubmed: 31004545
Biol Blood Marrow Transplant. 2014 Jan;20(1):46-52
pubmed: 24120526
Blood. 2014 Jun 5;123(23):3664-71
pubmed: 24744269
Blood. 2016 May 19;127(20):2427-38
pubmed: 26884374
Biol Blood Marrow Transplant. 2018 Jun;24(6):1237-1242
pubmed: 29378303
J Virol. 2011 Feb;85(3):1310-21
pubmed: 21084470
PLoS One. 2017 Aug 11;12(8):e0178763
pubmed: 28800601
Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56
pubmed: 16338616
Eur J Immunol. 2000 Jun;30(6):1676-82
pubmed: 10898504
J Immunol. 2017 Jul 15;199(2):792-805
pubmed: 28630092
Biol Blood Marrow Transplant. 2005 Mar;11(3):231-9
pubmed: 15744242
J Infect Dis. 2017 Nov 15;216(8):945-956
pubmed: 29029297
PLoS One. 2018 Feb 28;13(2):e0193554
pubmed: 29489900
Front Immunol. 2017 Nov 21;8:1591
pubmed: 29209324
Hum Immunol. 2003 Apr;64(4):440-52
pubmed: 12651070
Zhonghua Nei Ke Za Zhi. 2016 Feb;55(2):107-10
pubmed: 26875578
Biol Blood Marrow Transplant. 2009 Dec;15(12):1543-54
pubmed: 19896078
Biol Blood Marrow Transplant. 2016 Jan;22(1):141-8
pubmed: 26415558
Biol Blood Marrow Transplant. 2015 Nov;21(11):2008-16
pubmed: 26211985
J Clin Immunol. 2005 Sep;25(5):473-81
pubmed: 16160916
J Virol. 2003 May;77(9):5226-40
pubmed: 12692225
Front Immunol. 2017 Dec 11;8:1776
pubmed: 29312307
Bone Marrow Transplant. 2005 Nov;36(9):803-11
pubmed: 16113668
PLoS One. 2014 Apr 23;9(4):e94892
pubmed: 24760079
Science. 2002 Mar 15;295(5562):2097-100
pubmed: 11896281
PLoS Pathog. 2013;9(5):e1003383
pubmed: 23717207
Blood. 2005 Oct 15;106(8):2912-9
pubmed: 15994282
Front Immunol. 2018 Mar 01;9:389
pubmed: 29545802
Biol Blood Marrow Transplant. 2018 Feb;24(2):353-358
pubmed: 28986189
Br J Haematol. 2010 Jan;148(2):311-22
pubmed: 20095088
Transplantation. 1974 Oct;18(4):295-304
pubmed: 4153799
J Virol. 1996 Nov;70(11):7569-79
pubmed: 8892876
Blood. 2016 Jul 21;128(3):456-9
pubmed: 27216219
J Virol. 2009 Sep;83(18):9611-5
pubmed: 19553308
Mol Immunol. 2006 Feb;43(6):559-69
pubmed: 15927255

Auteurs

Dolores Grosso (D)

Blood and Marrow Transplant Program, The Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA, United States.

Benjamin Leiby (B)

Pharmacology and Experimental Therapeutics, The Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA, United States.

Matthew Carabasi (M)

Blood and Marrow Transplant Program, The Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA, United States.

Joanne Filicko-O'Hara (J)

Blood and Marrow Transplant Program, The Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA, United States.

Sameh Gaballa (S)

Blood and Marrow Transplant Program, The Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA, United States.

William O'Hara (W)

Blood and Marrow Transplant Program, The Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA, United States.

John L Wagner (JL)

Blood and Marrow Transplant Program, The Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA, United States.

Neal Flomenberg (N)

Blood and Marrow Transplant Program, The Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA, United States.

Classifications MeSH